Tag: AML

2.1. Specificity SnoRNAs are ubiquitous and highly abundant RNAs [21,28]. So, how can one target the malignant cell with little to no harm to healthy cells? Recent publications have demonstrated that some rRNA modifications occur in sub-stoichiometric levels [10,29]. This finding has overturned the notion that all rRNA modifications are…

Methylation-based sequencing appears to be a viable risk-assessment tool for myelodysplastic syndromes (MDS), according to a study presented at the 2023 American Society of Clinical Oncology Annual Meeting. “MDS risk stratification is key for [making] optimal treatment decisions. DNA methylation is associated with MDS biology due to frequent somatic mutations…

Cold Spring Harb Mol Case Stud. 2023 Apr; 9(2): a006256. ,1,2 ,1,2 ,1,2 ,2,3 ,4 and 1,2 Mahvish Q. Rahim 1Pediatric Hematology Oncology, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, Indiana, USA; 2Riley Hospital for Children at Indiana University Health, Indianapolis, Indiana, USA; April Rahrig 1Pediatric Hematology Oncology,…

I see no post about this problem but I have a training speed issue using as_mount for the Blob Storage with DataLoader in PyTorch. The job is just downloading images (by batches only used once) from the blob (by mounting it : data = datastore.path(“./”).as_mount()) and training a neural net…

Invivoscribe and Complete Genomics said Friday that they are partnering to develop and commercialize biomarker tests. Under the terms of the deal, Invivoscribe will be responsible for the development of biomarker tests, including test controls and associated bioinformatics software. The tests will run on Complete Genomics’ next-generation sequencing (NGS) platforms….

SAN DIEGO and SAN JOSE, Calif. , June 2, 2023 /PRNewswire/ — Invivoscribe and Complete Genomics announced today that they had entered a partnership to develop and commercialize biomarker tests on Complete Genomics’ NGS platforms. The territory is worldwide, and the field is oncology and cancer research. Under the terms…

In 2020, there were more than 73,000 people living with acute myeloid leukemia (AML) in the United States. Approximately 31% of those with AML are estimated to survive 5 or more years after their diagnosis.1 Although a bone marrow transplant may increase that 5-year survival rate, the efficacy of the…

SAN DIEGO, May 26, 2023 /PRNewswire/ — Invivoscribe is pleased to announce that their LeukoStrat CDx FLT3 Mutation Assay® has received updated reimbursement by Japan’s Ministry of Health, Labor and Welfare (MHLW) to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may be…

SAN DIEGO, May 26, 2023 /PRNewswire/ — Invivoscribe is pleased to announce that their LeukoStrat CDx FLT3 Mutation Assay® has received updated reimbursement by Japan’s Ministry of Health, Labor and Welfare (MHLW) to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML) who may…

Results from Phase 3 COMMANDS study, selected for ASCO’s official press program,show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with concurrent hemoglobin increase vs. epoetin alfa, including in clinically relevant subgroups Reblozyl demonstrated a durable response, with nearly 2.5 years median transfusion independence, 1 year…

/EIN News/ — NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that a trial in progress poster for…

NEW YORK, May 25, 2023 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that a trial in progress poster for the Phase 3…

Treatment with voruciclib both with and without venetoclax (Venclexta) appears to be tolerable and efficacious for patients with relapsed/refractory acute myeloid leukemia (AML) and B-cell malignancies, according to a press release by MEI Pharma on early findings from a phase 1 study (NCT03547115). Voruciclib is an oral CDK9 inhibitor, hypothesized…

Transcript: Andre H. Goy, MD: We cure a very large fraction of patients with large cell lymphoma, and CAR [chimeric antigen receptor] T-cell therapy now cures a fraction of the patients. In large cell lymphoma, we probably cure close to 40% with anti-CD19 CAR T-cell therapy. So as you mentioned,…

PRESS RELEASE Published May 24, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….

Huang, H., Weng, H. & Chen, J. m6A modification in coding and non-coding RNAs: roles and therapeutic implications in cancer. Cancer Cell 37, 270–288 (2020). Article  CAS  PubMed  PubMed Central  Google Scholar  Qing, Y., Su, R. & Chen, J. RNA modifications in hematopoietic malignancies: a new research frontier. Blood 138,…

Rates of relapse and worse survival were associated with persistent FLT3-ITD or NPM1 variants prior to allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia. Detection by DNA sequencing of persistent FLT3-ITD or NPM1 variants – the two most common AML variants – in blood ahead of allogeneic hematopoietic cell transplantation (allo-HCT)…

Image Credit: © AkuAku [stock.adove.com] Infusions of SC-DARIC33, a chimeric antigen receptor (CAR) T-cell therapy, were well tolerated and did not show dose-limiting toxicities in patients with relapsed or refractory acute myeloid leukemia (AML) according to findings from the preliminary correlative analysis of the ongoing phase 1 PLAT-08 trial (NCT05105152).1…

Senti Biosciences, Inc. Five presentations showcase the modularity and applicability of Senti’s Gene Circuit technology in NK cells, T cells, AAVs, iPSCs, and macrophages SOUTH SAN FRANCISCO, Calif., May 20, 2023 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies…

The combination of rituximab (Rituxan), bendamustine (Bendeka), and low-dose cytarabine (R-BAC) without maintenance therapy maintained clinical efficacy after longer follow-up in a cohort of elderly patients with previously untreated mantle cell lymphoma (MCL), according to new findings from the phase 2 RBAC500 clinical trial (NCT01662050) published recently in Blood Advances….

GILEAD  AND  KITE  ONCOLOGY  TO  SHOWCASE  ADVANCES  ACROSS  THE  PIPELINE  AIMING  TO  ADDRESS  UNMET  NEEDS  IN  CANCER  CARE  AT  ASCO  2023 – Data Across 30 Abstracts Reinforce Leadership in Metastatic Breast Cancer and Demonstrate Breadth of Pipeline Across Lung, Haematologic, Genitourinary, Gastrointestinal, Gynaecological and Other Solid Tumours –   –…

HOUSTON, May 16, 2023 /PRNewswire/ — Iterion Therapeutics, a leading biopharmaceutical company dedicated to the development of innovative treatments for cancer, announced today its collaboration in a Phase 1 clinical trial for tegavivint in patients with relapsed or refractory c-Myc-overexpressing large B-cell lymphomas. The first patient has been enrolled to…

150 patients have been enrolled at the multi-clinical centers in US to the Phase 3 randomized trial of DFP-10917 vs non-intensive reinduction (LoDAC, Azacytidine, Decitabine, Venetoclax combo-regimens) or intensive reinduction (high and intermediate dose of Cytarabine regimens) in the 2nd, 3rd, or 4th salvage of AML and the 1st interim…

69 11.05.2023 – 16:59 Invivoscribe, Inc. San Diego (ots/PRNewswire) SAN DIEGO, May 11, 2023 /PRNewswire/– “We are pleased to announce today that the LeukoStrat® CDx flt3 -Invivoscribe’s mutation test has been approved by BSI (Netherlands) and EMA as a Class C CDx test that meets the stringent new IVDR requirements…

SAN DIEGO, May 11, 2023 /PRNewswire/ — “Today we are pleased to announce that Invivoscribe’s LeukoStrat® CDx FLT3 Mutation Assay has been approved by BSI (Netherlands) and the EMA as a Class C CDx assay, meeting the stringent new IVDR (Regulation (EU) 2017/746) requirements. Invivoscribe is one of the first companies…

– New preclinical data at AACR supports SENTI-202 as a potential first-in-class logic gated CAR-NK cell therapy; remains on track for IND submission and clearance in 2H 2023 – – Initial collaboration data with BlueRock and Spark to be presented at ASGCT, validating that Senti’s Gene Circuit enabled cell platform…

Brian A. Jonas, MD, associate professor of medicine at UC Davis Health in Sacramento, California, discusses studies investigating the use of uproleselan for the treatment of patients with acute myeloid leukemia (AML). Transcript: 0:08 | been a drug developed to target the e-selectin ligand interaction, it’s a so-called e-selecting antagonist and…

I am currently using h2o autoML to train a model on a binary classification problem. I have a train (70% ~200k rows), valid (10% ~30k rows), test (10% ~30k rows) and blend (10% ~30k rows) datasets all coming from the time sensitive splitting of the original dataset (~300k rows). When…

5-Azacytidine pretreatment resensitizes cisplatin-resistant DLBCL cell lines to cisplatin to varying degrees A platinum-based anti-neoplastic agent is an essential component of salvage regimens for aggressive lymphomas, for example, rituximab, gemcitabine, dexamethasone, and cisplatin (R-GDP) for relapsed/refractory DLBCL and Hodgkin lymphoma [21]. As a single agent in humans, cisplatin is administered…

Reported initial positive clinical data from first two cohorts of Phase II of ongoing Phase I/II study (COVALENT-111) of BMF-219, Biomea’s lead investigational, orally administered covalent menin inhibitor, as a novel, potentially disease-modifying treatment for patients with type 2 diabetes Continued enrolling four liquid tumor cohorts in ongoing Phase I…

Dr Eirini Papapetrou speaks to ecancer about her study which found that patient-derived iPSCs faithfully represent the genetic diversity and cellular architecture of human acute myeloid leukaemia. This study created a reprogramming method called “Complete Capture of Mutational Burden” (CCoMB). This method combines comprehensive genetic characterisation of the starting sample…

DiMasi, J. A., Grabowski, H. G. & Hansen, R. W. Innovation in the pharmaceutical industry: new estimates of R&D costs. J. Health Econ. 47, 20–33 (2016). Article  PubMed  Google Scholar  Wouters, O. J., McKee, M. & Luyten, J. Estimated research and development investment needed to bring a new medicine to…

–  24 leading bone marrow transplant (BMT) centers that perform over 30% of transplants in the U.S. participated in the SIERRA trial that enrolled patients with active relapsed or refractory acute myeloid leukemia –  Demonstration of rapid ability and ease of adoption for Iomab-B infusions at SIERRA sites NEW YORK,…

NEW YORK – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (‘Actinium’ or the ‘Company’), a leader in the development of targeted radiotherapies, today announced that the positive results from the pivotal Phase 3 SIERRA Trial of Iomab-B were presented in an oral presentation at the European Society for Blood and Marrow…

Michael Andreeff, MD, PhD The E-selectin inhibitor uproleselan (GMI-1271) has shown preliminary efficacy in patients with acute myeloid leukemia (AML), and E-selectin could represent one of several novel targets for treatment of this patient population, according to Michael Andreeff, MD, PhD. Previously, a phase 1/2 trial (NCT02306291) investigating uproleselan plus…

– EBMT oral presentation builds awareness for Iomab-B and the SIERRA trial results with the European transplant community that performs twice as many transplants compared to the U.S. – Iomab-B enabled unprecedented 100% bone marrow transplant access and engraftment with 75% post-BMT CR rate in patients with active, relapsed or…

News and research before you hear about it on CNBC and others. Claim your 1-week free trial to StreetInsider Premium here. Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”), a leader in the development of targeted radiotherapies, today announced that the positive results from the pivotal Phase 3…

–  EBMT oral presentation builds awareness for Iomab-B and the SIERRA trial results with the European transplant community that performs twice as many transplants compared to the U.S. –  Iomab-B enabled unprecedented 100% bone marrow transplant access and engraftment with 75% post-BMT CR rate in patients with active, relapsed or…

Actinium Pharmaceuticals (NYSE:), Inc. (NYSE AMERICAN: ATNM) (“Actinium” or the “Company”), a leader in the development of targeted radiotherapies, today announced that the positive results from the pivotal Phase 3 SIERRA Trial of Iomab-B were presented in an oral presentation at the European Society for Blood and Marrow Transplantation (EBMT)…

Typhoid GBD, Paratyphoid C. The global burden of typhoid and paratyphoid fevers: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Infect Dis. 2019;19(4):369–81. Article  Google Scholar  Arndt MB, Mosites EM, Tian M, Forouzanfar MH, Mokhdad AH, Meller M, Ochiai RL, Walson JL. Estimating the burden of…

Note: This article has been updated to reflect the correct revised PDUFA date. FDA has added 3 months to the review timeline for quizartinib, an investigational therapy for the treatment of adult patients with newly diagnosed FLT3-ITD-positive acute myeloid leukemia (AML), an aggressive form of the blood cancer. Daiichi Sankyo…

GAITHERSBURG, Md. and SHANGHAI, April 24, 2023 /PRNewswire/ — I-Mab (the “Company”) (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the first patient in a Phase 3 registrational trial (ClinicalTrials.gov Identifier: NCT05709093) in China for patients with higher-risk myelodysplastic syndrome…

Angelos Stergiou, MD, ScD hc An independent data monitoring committee (IDMC) has recommended that the phase 3 REGAL trial (NCT04229979) examining galinpepimut-S (GPS) in patients with acute myeloid leukemia (AML) continue as planned without modifications.1 The recommendation follows a positive prespecified risk-benefit assessment of unblinded data from the study. The…

PRESS RELEASE Published April 18, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight 2023,” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….

doi: 10.1158/2643-3230.BCD-22-0167. Online ahead of print. Andriana G Kotini #  1   2   3   4 , Saul Carcamo #  1   5 , Nataly Cruz-Rodriguez #  1   2   3   4 , Malgorzata Olszewska  1   2   3   4 , Tiansu Wang  1   2   3   4 , Deniz Demircioglu …

Caribou Biosciences Presents New Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the 2023 AACR Annual Meeting Details Category: DNA RNA and Cells Published on Tuesday, 18 April 2023 10:14 Hits: 247 — CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML…

SELLAS Life Sciences Group, Inc. has announced that the Independent Data Monitoring Committee (IDMC) overseeing the Phase 3 REGAL study for galinpepimut-S (GPS) in acute myeloid leukemia (AML) has given the green light for the trial to continue as planned without modifications. This is a positive development for the company,…

Tisch Cancer Center scientists report that they have developed novel models of the deadliest blood cancer, acute myeloid leukemia (AML), creating a “transformative resource” to study this cancer and eventually its drug response and drug resistance, according to research presented at the annual meeting of the American Association of Cancer…

Caribou Biosciences, Inc. — CB-012 genome-edited armoring strategy significantly reduced tumor burden and improved overall survival in AML xenograft models — — CB-012 IND-enabling studies ongoing; IND submission in r/r AML planned for H2 2023 — BERKELEY, Calif., April 17, 2023 (GLOBE NEWSWIRE) — Caribou Biosciences, Inc. (Nasdaq: CRBU), a…

Senti Biosciences, Inc. SOUTH SAN FRANCISCO, Calif., April 14, 2023 (GLOBE NEWSWIRE) — Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a biotechnology company innovating next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced its participation at the following investor conferences: Bank of America 2023 Global Healthcare…

Epigenetic alterations, such as DNA methylation aberrations, are a hallmark of human cancer. This observation has led to the assessment of hypomethylating agents (HMAs) as potential drugs to treat oncological patients, being considered the clinical approval of these pharmacological compounds in the therapy of myeloid malignancies as one of the…

NEW YORK – Function Oncology launched on Wednesday with $28 million in recently raised Series A funds and a CRISPR-Cas9 platform, which it hopes will help oncologists tailor patients’ treatments based on the function of their individual cancer genes. The San Diego-based firm is unveiling the first validation data of…

Image by Author   In today’s world, all organizations want to use Machine learning to analyze the data they generate daily from the users. With the help of a machine or deep learning algorithms, they can analyze the data. Afterwards, they can make the prediction of testing data in the…

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. Edmonton, Alberta, Canada/April 10, 2023- Pacylex Pharmaceuticals today announced it will be presenting at two exclusive life science startup events in Canada in April, spotlighting its emergence as one of the premier…

The use of high sensitivity DNA sequencing tests to measure residual disease in AML could improve identification of patients at risk for relapse or death. “In acute myeloid leukemia (AML), the association between measurable residual disease (MRD)—leukemic cells remaining in a patient during clinical remission but not detectable by standard…

Computational biologists at St. Jude categorized and identified the mechanism underlying oncogenic fusions in pediatric cancer cells. The researchers showed in mice that targeting oncogenic fusions that drive cancer with genome editing tools such as CRISPR has the potential to cure certain tumors. The findings were published in Nature Communications in…

In patients with acute myeloid leukemia (AML) in first remission, the persistence of certain DNA variants related to measurable residual disease (MRD) prior to allogeneic hematopoietic cell transplant (HCT) was associated with post-HCT relapse and worse survival outcomes in a recent study. The findings, published in JAMA, suggest that the…

Nanopore reads coupled to a novel computational method extends analyses of differential methylation to sparse CpGs (outside CpG islands) We analyzed tumor samples at diagnosis (T) and relapse (R) from three AML patients (UD5, UD10 and AML2) who received standard chemotherapy and relapsed with chemoresistant disease (supplementary Table 1). DNA from…

Yulia Gonskikh1,6, Julian Stoute1,2,6, Hui Shen1,6, Krista Budinich3,4,5, Bianca Pingul1,2, Kollin Schultz1,2, Heidi Elashal1,2, Ronen Marmorstein1,2, Junwei Shi3,4,5 and Kathy Fange Liu1,2 1Department of Biochemistry and Biophysics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA; 2Graduate Group in Biochemistry and Molecular Biophysics, Perelman School of Medicine, University…

The scientific foundation needed to work on curing a class of cancer-causing mutations is here, in the form of a tool from St. Jude Children’s Research Hospital. Computational biologists at St. Jude comprehensively categorized and identified the mechanism underlying oncogenic fusions in pediatric cancer cells. Oncogenic fusions are mutations that…

FG spectrum in pediatric AML patients A combinatorial approach, including conventional and next-generation sequencing (NGS)-based assays, was employed to profile the FG landscape (see Methods). FG analysis was feasible for 138 patients (94% of the entire cohort, Supplementary Data 1) from whom suitable testing materials were available. The most common FGs…

The CRISPR & Cas Genes market growth is driven by increasing number of clinical trials associates with CRIPR technology and rising of development of novel technologies. The CRISPR & Cas genes market revenue will reach at USD 8.96 billion by 2030 with a CAGR of around 17.03% from 2022 to…

We are seeking a Postdoctoral Fellow with computational/bioinformatics background to work on functional and immunogenomic profiling focusing on leukemia. Our lab conducts single cell, bulk, spatial and CRISPR profiling of AML and immune cells. Our goal is to apply innovative functional genomics, immunogenomics, and bioinformatics approaches to better understand leukemogenesis,…

Introduction Bacteriophage (phage) is a class of widespread viruses exclusively infecting bacteria, playing a key role in ecosystems.1–3 Since phages were discovered over a hundred years ago, many techniques and reagents, such as DNA polymerase, restriction endonuclease, ligase, and CRISPR/Cas system, have been developed from phages, which have together accelerated…

Job description This is an exciting opportunity to be a key member of a team that is researching the genomic origins of inflammatory disease and myeloid cancers.  We are studying clonal haematopoiesis or CHIP, where individuals acquire mutations in blood cells without apparent blood disease, and these mutations occur in…

Illumina is releasing a new cloud-based, customizable platform that enables tertiary analysis for clinical NGS data, which the company says will streamline interpretation and reporting for a diverse range of application areas. Through application programming interface (API)-based calls, the platform will allow labs to scale up their NGS applications and…

Dual target therapy reduces DLBCL recurrence Non-Hodgkin’s lymphoma is one of the ten most common cancers in Hong Kong, and diffuse large B-cell lymphoma (DLBCL) is the most common type, accounting for about 30% to 40% of cancers. Although the traditional treatment has achieved good results in the past 20…

Expanded clinical development footprint of BMF-219, the company’s lead investigational, orally administered, covalent menin inhibitor, to eight liquid and solid tumor indications and type 2 diabetes across three ongoing clinical trials COVALENT-101 (Phase I study) enrolling four liquid tumor cohorts, each focused on distinct patient subsets of acute lymphocytic and…

PRESS RELEASE Published March 23, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight 2023,” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….

This is the post/tutorial where Dr Kevin Blighe showed how to perform survival analysis with gene here in this he showed how to use single gene as predictor and create groups based on expression and classify them as mid or high or low. Now How to do the same with…

The FDA has granted orphan drug designation to the investigational dual FLT-3 and Aurora kinase inhibitor EP0042 for the treatment of pretreated acute myeloid leukemia (AML), according to a press release from Ellipses Pharma.1 “The designation is an important milestone in the development of EP0042 and underscores the work we…

Immunotherapy has been widely studied in cancer treatment research, ever since William Coley, who is regarded as the father of immunotherapy, first attempted to leverage the immune system for oncological therapy in 1891. Soon enough, the transformative power of cancer vaccines were observed where tumor-specific antigens triggered antitumor immune responses….

Introduction You’ve been training your PyTorch models on your machine, and getting by just fine. Why would you want to train and deploy them in the cloud? Training in the cloud will allow you to handle larger ML models and datasets than you could train on your development machine. And…

There was good and bad news this week from Japanese company Astellas Pharma Inc. as one of its trials yielded positive results, while another didn’t meet its endpoints. Astellas Pharma announced pivotal phase 3 results for its study of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment…

. 2023 Feb 22;15(5):1386. doi: 10.3390/cancers15051386. Affiliations Expand Affiliations 1 Department of Haematology, School of Medical Sciences, Health Campus, Universiti Sains Malaysia, Kubang Kerian 16150, Malaysia. 2 Clinical Haematology Referral Laboratory, Haematology Department, Hospital Ampang, Ministry of Health Malaysia, Ampang 68000, Malaysia. 3 Department of Biomedical Science, College of Health…

People with a third copy of chromosome 21, known as trisomy 21, are at high risk of developing Acute Myeloid Leukaemia (AML), an aggressive form of blood cancer. Scientists led by the Department of Paediatrics at University Hospital Frankfurt have now identified the cause: although the additional chromosome 21 leads…

— CB-010 ANTLER Phase 1 trial in r/r B-NHL ongoing with update planned for H2 2023 — — CB-011 CaMMouflage Phase 1 trial in r/r MM recruiting patients at dose level 1 — — CB-012 IND-enabling studies initiated; IND submission in r/r AML planned for H2 2023 — — $317.0…

QIAGEN N.V.QGEN recently announced that it has entered into a strategic partnership with Servier. The agreement is intended to develop a companion diagnostic test for TIBSOVO — an isocitrate dehydrogenase-1 or IDH1 inhibitor indicated for treating the blood cancer acute myeloid leukemia or AML. For investors’ note, QIAGEN has master…

Hello there, I’m trying to download TARGET-AML data via GDCquery: library(TCGAbiolinks) query_target <- GDCquery(project = “TARGET-AML”, data.category = “Transcriptome Profiling”, data.type = “Gene Expression Quantification”, workflow.type = “STAR – Counts”) And I got this error: Warning messages: 1: In open.connection(con, “rb”) : URL ‘https://api.gdc.cancer.gov/files/?pretty=true&expand=cases,cases.samples.portions.analytes.aliquots,cases.project,center,analysis,cases.samples&size=10246&filters=%7B%22op%22:%22and%22,%22content%22:[%7B%22op%22:%22in%22,%22content%22:%7B%22field%22:%22cases.project.project_id%22,%22value%22:[%22TARGET-AML%22]%7D%7D,%7B%22op%22:%22in%22,%22content%22:%7B%22field%22:%22files.data_category%22,%22value%22:[%22Transcriptome%20Profiling%22]%7D%7D,%7B%22op%22:%22in%22,%22content%22:%7B%22field%22:%22files.data_type%22,%22value%22:[%22Gene%20Expression%20Quantification%22]%7D%7D,%7B%22op%22:%22in%22,%22content%22:%7B%22field%22:%22files.analysis.workflow_type%22,%22value%22:[%22STAR%20-%20Counts%22]%7D%7D]%7D&format=JSON’: Timeout of 60 seconds was reached…

Entered into a €40 million credit facility with the European Investment Bank and closed an approximatively $25 million follow-on equity offering to support Cellectis’ research, development and innovation activities Positive preliminary clinical data from Phase 1 BALLI-01 study (evaluating UCART22) for patients with r/r B-cell ALL presented…

NEW YORK – Using DNA sequencing to detect measurable residual disease (MRD) in acute myeloid leukemia (AML) patients about to undergo a stem cell transplant can help predict who will have their disease recur, according to a new study by researchers at the US National Heart, Lung, and Blood Institute…

TOKYO and ROCKVILLE, Md., March 9, 2023 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) today announced topline results from the Phase 3 MORPHO clinical trial evaluating gilteritinib as a maintenance therapy following…

HOUSTON ― The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless collaboration between MD Anderson’s world-leading clinicians and scientists, bringing discoveries from the lab to the clinic and back. Recent developments include…

Importance: Preventing relapse for adults with acute myeloid leukemia (AML) in first remission is the most common indication for allogeneic hematopoietic cell transplant. The presence of AML measurable residual disease (MRD) has been associated with higher relapse rates, but testing is not standardized. Objective: To determine whether DNA sequencing to…

News Release Tuesday, March 7, 2023 A small portion of adults in remission from a deadly blood cancer had persisting mutations that were detected, which predicted their risk of death from having the cancer return. Researchers at the National Institutes of Health show the benefits of screening adult patients in remission from acute…

Incidence of certain second primary malignancies (SPMs) were associated with increased overall survival (OS) among patients with multiple myeloma (MM), according to abstract findings presented at the 64th American Society of Hematology Meeting and Exposition.1 There is significant literature regarding the incidence of SPMs in patients with MM, in which…

The protein complex cohesin is fundamental to the cell division process, as it holds sister chromatids tightly together in a ringlike structure before a cell physically splits. But now researchers at the National Cancer Institute (NCI) have uncovered that the protein complex has another function, too—one that can answer questions…

Actinium Pharmaceuticals (NYSE:), Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it will host a key opinion leader (KOL) webinar at 8 a.m. EST on Tuesday, February 28, 2023, to discuss the results from the recently completed pivotal Phase…

Mocravimod is the only S1PR modulator being developed as an adjunctive and maintenance treatment for blood cancers Dublin, Ireland – February 27th, 2023 – Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound mocravimod, today announced that it received clearance from the Pharmaceuticals and Medical Devices…

Mocravimod is the only S1PR modulator being developed as an adjunctive and maintenance treatment for blood cancers Dublin, Ireland – February 27th, 2023 – Priothera, a late-clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound mocravimod, today announced that it received clearance from the Pharmaceuticals and Medical Devices…

Background Lymphoma is a group of heterogeneous hematological malignancies, which are classified into Hodgkin’s lymphoma (HL) and non-Hodgkin’s lymphoma (NHL). Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive NHL. DLBCL can be divided into germinal center B-cell-like (GCB) subgroup and non-GCB subgroup according to the origin of cells….

Our management’s discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements included in this Annual Report on Form 10-K, which have been prepared by us in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) and…

Targeted drugs have been developed to supplement chemotherapy in the treatment of cancer. These drugs only affect cancer cells, leaving healthy cells alone.  Venetoclax is a new targeted therapy option for the treatment of acute myeloid leukemia (AML). It was recently granted marketing authorization in Finland. Venetoclax works by sensitizing…

NEW YORK and LONDON, Feb. 21, 2023 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced the late-breaker presentation of a patient case study from the Phase 3 Part A clinical trial of nomacopan in pediatric hematopoietic…

PRESS RELEASE Published February 21, 2023 DelveInsight’s, “NK Cell Therapy Pipeline Insight, 2023,” report provides comprehensive insights about 100+ companies and 185+ pipeline drugs in the NK Cell Therapy pipeline landscape. It covers the NK Cell Therapy pipeline drug profiles, including NK Cell Therapy clinical trials and nonclinical stage products….

The use of the precision cellular therapy Orca-T demonstrated promising efficacy effects at a median follow-up of 1 year in patients with acute leukemia or high-risk myelodysplastic syndrome (MDS) in an early analysis of a phase 1b and 2 study that have yet to be reported, according to data presented…

–  Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission after BMT with high statistical significance (p-value of <0.0001), 22% of patients achieved dCR in the Iomab-B arm compared to 0% in the control arm –  In patients achieving 6-month dCR with Iomab-b,…

NEW YORK – Pfizer (NYSE: PFE) announced today positive results from the Phase 3 TALAPRO-2 study of TALZENNA (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with XTANDI, demonstrating a statistically significant and clinically meaningful improvement in radiographic progression-free survival compared to placebo plus XTANDI in men with metastatic…

ROCKVILLE, Md – GlycoMimetics, Inc. (Nasdaq: GLYC) today announced the independent Data Monitoring Committee (DMC) reviewed the interim utility analysis of its Phase 3 study of uproleselan in relapsed/refractory (R/R) acute myeloid leukemia (AML) and recommended the study should continue to the originally planned final overall survival event trigger. ‘We…

An independent data monitoring committee (IDMC) has recommended that a phase 3 trial (NCT03616470) evaluating uproleselan (GMI-1271) plus chemotherapy for patients with relapsed/refractory acute myeloid leukemia (AML) should continue to the planned overall survival (OS) event trigger.1 The IDMC conducted an interim utility analysis using a very high statistical threshold…